Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

First-Line Therapy for dMMR mEC: Patient Conversations and Treatment Goals

October 18th 2022

Comprehensive discussion on patient counseling, and treatment goals, and expectations for those beginning first-line chemotherapy for dMMR metastatic endometrial cancer.

Pembrolizumab Delivers Promising Results in Advanced Clear Cell Gynecologic Cancer

October 17th 2022

Pembrolizumab monotherapy induced durable clinical outcomes in heavily pretreated patients with clear cell gynecologic cancer.

Letrozole Plus Abemaciclib Elicits Promising Responses in ER+ Endometrial Cancer

October 14th 2022

Dual inhibition with letrozole and abemaciclib displayed response and survival benefits in patients with recurrent estrogen receptor–positive endometrioid endometrial cancer.

EMA Endorses Cemiplimab Approval in Advanced Cervical Cancer

October 14th 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for cemiplimab monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after platinum-based chemotherapy.

Mirvetuximab Soravtansine Generates Improvement in PROs Vs Chemotherapy in Advanced Ovarian Cancer

October 13th 2022

Treatment with mirvetuximab soravtansine elicited a statistically significant benefit vs investigator’s choice of chemotherapy for the OV28 abdominal/gastrointestinal symptom subscale in patients with folate receptor alpha–positive, advanced ovarian cancer.

GX-188E Plus Pembrolizumab Proves Safe, Effective in HPV16/18+ Recurrent or Metastatic Cervical Cancer

October 13th 2022

The therapeutic DNA vaccine, GX-188E, in combination with pembrolizumab produced encouraging responses in patients with human papillomavirus 16- or 18-positive, recurrent or metastatic cervical cancer who did not respond to standard-of-care treatment.

Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status

October 12th 2022

González-Martín discusses the updated long-term efficacy and safety data from the PRIMA study, the importance of utilizing PARP inhibitors in patients with homologous recombination–deficient tumors, and the benefit observed with niraparib in those with homologous recombination–proficient tumors.

TQB2450 Plus Anlotinib Elicits Antitumor Activity in Advanced Endometrial Cancer

October 11th 2022

The combination of TQB2450 plus anlotinib generated responses and showcased a manageable safety profile in patients with recurrent or metastatic advanced endometrial cancer, according to data from the phase 2 TQB2450 II 08 trial.

Dostarlimab Elicits Survival Benefit in dMMR/MSI-H Advanced Endometrial Cancer

October 11th 2022

Single-agent dostarlimab-gxly produced progression-free survival and overall survival benefits in patients with advanced or recurrent mismatch repair–deficient/microsatellite instability–high endometrial cancer.

Expert Commentary on the Patient’s Treatment Plan

October 11th 2022

Expert oncologists discuss the patient’s first-line treatment plan and comment on how they would have approached her care.

A Review of mEC Incidence and Prognosis and Introduction of the Clinical Case

October 11th 2022

Drs Kathleen Moore and David O’Malley share their perspectives on the incidence and prognosis of mEC, including mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) disease, and then review a scenario of a patient with dMMR mEC who was treated with first-line carboplatin/paclitaxel.

FDA Approves Bevacizumab-adcd Biosimilar in Six Solid Tumors

September 28th 2022

The FDA has approved bevacizumab-adcd, a bevacizumab biosimilar, for the treatment of six types of cancer.

Updated Efficacy and Safety of Lenvatinib Plus Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Advanced Endometrial Cancer: Study 309/KEYNOTE-775

September 28th 2022

Dr Domenica Lorusso reviews data updates from KEYNOTE-775 that were recently presented at the European Society for Medical Oncology (ESMO) Congress 2022.

Pafolacianine Detects Microlesions in Folate Receptor–Positive Ovarian Cancer

September 27th 2022

Pafolacianine used during ovarian cancer surgery identified additional tumors that were not detected with conventional means and not otherwise planned for resection, according to results from a phase 3 study recently published in the Journal of Clinical Oncology.

Intensity-Modulated Radiation Therapy Decreases GI and Urinary Toxicity in Endometrial and Cervical Cancer

September 26th 2022

Intensity-modulated radiation therapy elicited durable efficacy and a favorable safety profile compared with conventional radiotherapy in patients with endometrial and cervical cancers who received postoperative pelvic radiation.

Dostarlimab Provides Survival Benefits in dMMR Endometrial Cancer and Other Solid Tumors

September 22nd 2022

Single-agent dostarlimab showcased durable antitumor activity in patients with mismatch repair–deficient endometrial cancer and other solid tumors, with landmark estimates at various time points underscoring stable progression-free survival benefits in responders.

Niraparib Maintenance Provides Durable Long-term Remission in High-Risk Advanced Ovarian Cancer

September 15th 2022

Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.

FDA and EU Approval Sought for Rucaparib as Frontline Maintenance in Select Advanced Ovarian Cancer

September 13th 2022

A supplemental new drug application and a Type II variation has been submitted to the FDA and the European Medicines Agency, respectively, seeking the approval of rucaparib as frontline maintenance treatment in women with advanced ovarian cancer irrespective of biomarker status who have responded to first-line platinum-based chemotherapy.

Rucaparib Maintenance Elicits PFS Benefit in Newly Diagnosed Ovarian Cancer

September 11th 2022

First-line rucaparib maintenance therapy improved progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, according to disease risk subgroup analyses from the phase 3 ATHENA–MONO study.

Lenvatinib/Pembrolizumab Combo Improves Survival, Responses in Advanced Endometrial Cancer

September 11th 2022

Lenvatinib plus pembrolizumab maintained clinically meaningful benefits in outcomes vs physician’s choice of therapy for patients with advanced endometrial cancer who received prior platinum-based chemotherapy.